Overview
Zhenyu Nie practices practicing medicine in Changsha, China.
Nie is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Bladder Cancer, Cerebral Hypoxia, Familial Prostate Cancer, and Renal Cell Carcinoma (RCC).
They are actively involved in clinical research, co-authoring 22 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Zhenyu Nie
Is Zhenyu Nie a top-rated expert for Bladder Cancer?
MediFind is an objective health platform that identifies experts based on real-world data. Zhenyu Nie is classified as an Advanced expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Zhenyu Nie participate in research or clinical trials?
Yes. Zhenyu Nie has published 22 articles and abstracts on conditions like Bladder Cancer. You can view a list of Zhenyu Nie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Bladder CancerNie isAdvanced. Learn about Bladder Cancer.
- Experienced
- Cerebral HypoxiaNie isExperienced. Learn about Cerebral Hypoxia.
- Familial Prostate CancerNie isExperienced. Learn about Familial Prostate Cancer.
- Renal Cell Carcinoma (RCC)